Botulinum Toxin A Injection – Uses, Dosage, Side Effects, Cost | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Botulinum Toxin A
Therapeutic Class: Neurotoxin
Subclass: Neuromuscular Blocking Agent
Speciality: Neurology
Schedule (India): Schedule H
Route(s): Intramuscular, Intradermal, Intravesical (specialist only)
Formulations Available in India:
- Injection: 100 units/vial (lyophilised powder for reconstitution)
- Injection: 200 units/vial (lyophilised powder for reconstitution)
- Injection: 300 units/vial (Dysport — units not interchangeable)
- Injection: 500 units/vial (Dysport — units not interchangeable)
Note: Units are NOT interchangeable between brands. Botox/Xeomin units differ from Dysport units. Dosing must follow product-specific guidelines.
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
▶ 1. Cervical Dystonia (Spasmodic Torticollis) — Adults
| Parameter | Recommendation |
|
Starting dose
|
120–200 units total, divided among affected neck muscles (sternocleidomastoid, splenius capitis, trapezius, levator scapulae) |
|
Titration
|
Adjust based on clinical response and muscle mass; increase by 50–100 units per cycle if inadequate response |
|
Usual maintenance dose
|
150–300 units per session every 12–16 weeks |
|
Maximum dose
|
400 units per session |
Clinical Notes:
- EMG or ultrasound guidance recommended for precise muscle localisation
- Response typically begins within 2 weeks; peak effect at 4–6 weeks
- Do not re-inject before 12 weeks
▶ 2. Blepharospasm and Hemifacial Spasm — Adults
| Parameter | Recommendation |
|
Starting dose
|
1.25–2.5 units per injection site into orbicularis oculi; total 12–25 units per eye |
|
Titration
|
Increase by 1.25 units per site based on response |
|
Usual maintenance dose
|
25–50 units total (both eyes) every 12–16 weeks |
|
Maximum dose
|
100 units per session (both eyes combined) |
Clinical Notes:
- Inject medially into orbicularis to reduce ptosis risk
- Avoid injection near levator palpebrae superioris
▶ 3. Strabismus — Adults
| Parameter | Recommendation |
|
Starting dose
|
1.25–2.5 units for vertical muscles and small deviations; 2.5–5 units for horizontal rectus muscles |
|
Titration
|
Re-inject after 7–14 days if initial response inadequate |
|
Usual maintenance dose
|
2.5–5 units per muscle |
|
Maximum dose
|
25 units per muscle per session |
Clinical Notes:
- EMG guidance mandatory
- Specialist ophthalmologist administration only
▶ 4. Post-Stroke Upper Limb Spasticity — Adults
| Parameter | Recommendation |
|
Starting dose
|
75–150 units total, distributed across affected muscles (biceps, flexor carpi radialis/ulnaris, finger flexors) |
|
Titration
|
Increase by 50–100 units per cycle based on Modified Ashworth Scale improvement |
|
Usual maintenance dose
|
200–300 units per session every 12–16 weeks |
|
Maximum dose
|
400 units per session across all upper limb muscles |
Clinical Notes:
- Combine with physiotherapy for optimal functional outcomes
- Ultrasound-guided injection improves accuracy
- Document baseline spasticity scores for monitoring
▶ 5. Overactive Bladder (Idiopathic) — Adults
| Parameter | Recommendation |
|
Starting dose
|
100 units intravesically, distributed across 20 injection sites in detrusor muscle |
|
Titration
|
Not applicable |
|
Usual maintenance dose
|
100 units per session |
|
Maximum dose
|
100 units per session; re-injection not before 12 weeks |
Clinical Notes:
- Cystoscopic administration under local/general anaesthesia
- Post-void residual monitoring mandatory
- Patient must be willing to self-catheterise if retention occurs
▶ 6. Neurogenic Detrusor Overactivity — Adults (Specialist Only)
| Parameter | Recommendation |
|
Starting dose
|
200 units intravesically, distributed across 30 injection sites |
|
Titration
|
Reduce to 100 units if excessive weakness or retention |
|
Usual maintenance dose
|
200 units per session every 12–16 weeks |
|
Maximum dose
|
200 units per session |
Clinical Notes:
- Associated with spinal cord injury, multiple sclerosis
- Higher retention risk; ensure catheterisation capability
▶ 7. Chronic Migraine Prophylaxis — Adults (Specialist Only)
| Parameter | Recommendation |
|
Starting dose
|
155 units total, divided across 31 injection sites (frontalis, corrugator, procerus, occipitalis, temporalis, trapezius, cervical paraspinals) |
|
Titration
|
May increase to 195 units across 39 sites if additional trigger areas identified |
|
Usual maintenance dose
|
155–195 units every 12 weeks |
|
Maximum dose
|
195 units per session |
Clinical Notes:
- Only for chronic migraine (≥15 headache days/month for ≥3 months, with ≥8 migraine days)
- Assess efficacy after 2 treatment cycles (24 weeks)
- Not indicated for episodic migraine
▶ 8. Primary Axillary Hyperhidrosis — Adults
| Parameter | Recommendation |
|
Starting dose
|
50 units per axilla (100 units total), intradermal injection |
|
Titration
|
Not typically required |
|
Usual maintenance dose
|
50 units per axilla every 6–9 months |
|
Maximum dose
|
100 units per axilla per session |
Clinical Notes:
- Perform Minor’s starch-iodine test to map hyperhidrotic area
- Multiple intradermal injections spaced 1–2 cm apart
Secondary Indications — Adults (Off-label, if any)
| Indication | Dose | Duration | Notes |
|
Sialorrhoea (Parkinson’s disease, ALS)
|
30–100 units total divided between parotid (20–30 units each) and submandibular glands (10–15 units each) | Re-inject every 3–4 months | OFF-LABEL; Ultrasound-guided; Specialist only; Supported by RCTs (Lagalla et al., Neurology India practice) |
|
Bruxism
|
20–30 units per masseter muscle bilaterally (total 40–60 units) | Re-inject every 3–6 months | OFF-LABEL; Specialist only; Case series evidence |
|
Anal Fissure (chronic)
|
20–40 units into internal anal sphincter | Single injection; may repeat after 3 months | OFF-LABEL; Specialist only; Used in Indian surgical practice |
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
▶ 1. Cerebral Palsy — Limb Spasticity
| Age Group | Starting Dose | Titration | Maximum Dose |
|
≥2 years
|
1–2 units/kg per muscle group | Increase by 1 unit/kg per cycle based on response | Lower of: 300 units total OR 12 units/kg per session |
|
Adolescents (≥12 years)
|
2–6 units/kg per muscle group | As per adult principles | 400 units per session |
Muscle-Specific Guidance:
- Gastrocnemius/soleus: 3–6 units/kg per leg
- Hamstrings: 2–4 units/kg per leg
- Adductors: 2–4 units/kg per leg
Clinical Notes:
- Repeat every 12–16 weeks
- Combine with physiotherapy, orthoses, serial casting
- Monitor for generalised weakness
▶ 2. Paediatric Strabismus (≥12 months)
| Age | Starting Dose | Maximum Dose |
| 12–24 months | 1.25 units per muscle | 2.5 units per muscle |
| >2 years | 1.25–2.5 units for small deviations; up to 5 units for larger | 25 units per muscle |
Clinical Notes:
- EMG-guided injection mandatory
- Specialist paediatric ophthalmologist only
- Re-injection after 3–6 months if needed
Secondary Indications — Paediatrics (Off-label, if any)
| Indication | Dose | Duration | Notes |
|
Neurogenic Detrusor Overactivity (spina bifida)
|
5–10 units/kg intravesically (max 200 units) | Re-inject every 6–9 months | OFF-LABEL; Under general anaesthesia; Specialist only; Used in Indian tertiary centres (AIIMS protocols) |
Age Restriction Statement:
- Not recommended below 2 years of age except under specialist supervision in tertiary centres
- Below 12 months: Only in exceptional circumstances with paediatric neurology/rehabilitation input
Safety Monitoring:
- Post-injection observation for 2–4 hours
- Monitor for dysphagia, respiratory difficulty, generalised weakness
- Ensure caregiver awareness of warning signs
RENAL ADJUSTMENT
- No dose adjustment required
- Botulinum toxin acts locally at neuromuscular junction; negligible systemic absorption
- General caution in frail patients with multiple comorbidities
HEPATIC ADJUSTMENT
| Severity | Recommendation |
|
Mild impairment
|
No dose adjustment required |
|
Moderate impairment
|
No dose adjustment required |
|
Severe impairment
|
No specific data; use with caution under specialist supervision |
CONTRAINDICATIONS
- Known hypersensitivity to botulinum toxin type A or formulation excipients (human albumin, sucrose)
- Infection at proposed injection site
- Generalised disorders of neuromuscular transmission (myasthenia gravis, Lambert-Eaton myasthenic syndrome)
- Coexisting therapy with aminoglycosides at time of planned injection (postpone botulinum)
- Pregnancy (Category C — avoid unless absolutely necessary)
CAUTIONS
- Pre-existing swallowing or breathing difficulties — increased aspiration risk with cervical/bulbar injections
- History of aspiration pneumonia
- Patients on anticoagulants — increased bruising risk; hold if feasible
- Neuromuscular disorders (motor neurone disease, peripheral neuropathies) — unpredictable response
- Previous non-response to botulinum toxin — consider neutralising antibodies
- High cumulative doses over time — antibody formation risk
- Elderly and frail patients — enhanced sensitivity
- Children <2 years — very limited safety data
PREGNANCY
| Parameter | Recommendation |
|
Risk Category
|
Category C — Avoid unless clearly necessary |
|
Safety Data
|
Animal studies show developmental toxicity; no adequate human data |
|
Preferred Alternatives
|
Physiotherapy, oral baclofen (with caution), conservative management |
|
When May Be Used
|
Only for severe, debilitating dystonia when no alternatives exist; specialist decision |
|
Monitoring
|
Fetal well-being via ultrasound if administered in 2nd/3rd trimester |
LACTATION
| Parameter | Recommendation |
|
Compatibility
|
Likely compatible due to large molecular size and local action |
|
Expected Levels in Milk
|
Negligible — systemic absorption minimal |
|
Preferred Alternatives
|
None specifically; may continue breastfeeding |
|
Infant Monitoring
|
Feeding difficulty, hypotonia, poor weight gain (unlikely but monitor) |
|
Recommendation
|
Avoid unless essential; if used, short-term breastfeeding interruption not mandatory |
ELDERLY
| Parameter | Recommendation |
|
Starting Dose
|
Use lower end of dose range (reduce by 20–30% from standard adult) |
|
Titration
|
Slower titration; extend interval between sessions if needed |
|
Extra Risks
|
Increased sensitivity to neuromuscular effects; dysphagia risk with cervical injections; falls risk; aspiration pneumonia |
|
Monitoring
|
Close observation for 48 hours post-injection; assess swallowing before discharge |
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
|
Aminoglycosides (gentamicin, amikacin, streptomycin)
|
Potentiate neuromuscular blockade; risk of respiratory compromise | Avoid concurrent use; delay botulinum if aminoglycoside therapy ongoing |
|
Non-depolarising muscle relaxants (vecuronium, atracurium)
|
Additive neuromuscular blockade | Avoid elective procedures requiring NMBAs within 2–4 weeks of botulinum |
|
Other botulinum toxin products
|
Cumulative toxicity; unpredictable blockade | Do not administer different botulinum products concurrently |
|
Spectinomycin, polymyxins
|
Potentiate neuromuscular blockade | Avoid combination |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
|
Anticholinergics (oxybutynin, tolterodine)
|
Additive anticholinergic effects; urinary retention risk with intravesical use | Monitor for retention; avoid combination in bladder indications unless specialist supervised |
|
Anticoagulants/Antiplatelets (warfarin, aspirin, clopidogrel)
|
Increased bruising at injection sites | Consider temporary hold if feasible; apply pressure post-injection |
|
Quinidine
|
May potentiate neuromuscular effects | Use with caution; monitor for weakness |
|
Magnesium sulphate
|
Potentiates neuromuscular blockade | Caution in eclampsia management if botulinum recently administered |
|
Benzodiazepines
|
Additive muscle weakness | Use cautiously in elderly; monitor for falls |
COMMON ADVERSE EFFECTS
- Injection site pain, erythema, bruising
- Localised muscle weakness (intended effect may extend beyond target)
- Headache (particularly with migraine prophylaxis indication)
- Ptosis (with periocular injections)
- Dysphagia (with cervical/neck injections; 10–20%)
- Dry mouth (with sialorrhoea or hyperhidrosis treatment)
- Flu-like symptoms
- Fatigue
SERIOUS ADVERSE EFFECTS
- Generalised muscle weakness — rare; may be life-threatening; requires immediate medical attention
- Respiratory compromise/failure — especially with high doses or pre-existing respiratory conditions
- Aspiration pneumonia — secondary to dysphagia; higher risk in elderly and those with bulbar dysfunction
- Anaphylaxis — rare; discontinue and treat as emergency
- Distant spread of toxin effect — weakness in muscles remote from injection site; Black Box Warning equivalent
- Urinary retention — with intravesical use; may require catheterisation
Action: Discontinue immediately and provide supportive care if generalised weakness or respiratory compromise suspected.
MONITORING REQUIREMENTS
| Phase | Parameters |
|
Baseline
|
Neuromuscular function assessment; document severity scores (Modified Ashworth Scale for spasticity, TWSTRS for cervical dystonia); swallowing assessment if cervical injection planned |
|
Post-injection (48–72 hours)
|
Observe for dysphagia, respiratory difficulty, generalised weakness; advise patient/caregiver on warning signs |
|
Short-term (2–4 weeks)
|
Assess clinical response; document improvement |
|
Long-term
|
Re-evaluate efficacy every 3–4 months; monitor for development of neutralising antibodies (reduced efficacy over time); reassess benefit-risk at each cycle |
BRANDS AVAILABLE IN INDIA
- BOTOX® (Allergan/AbbVie) — 100 units, 200 units/vial
- Xeomin® (Merz Pharma) — 100 units/vial
- Dysport® (Ipsen) — 300 units, 500 units/vial (Note: Dysport units NOT interchangeable with Botox/Xeomin)
PRICE RANGE (INR)
| Brand | Strength | Approximate Price |
| BOTOX® | 100 units | ₹14,000–18,000 per vial |
| BOTOX® | 200 units | ₹26,000–32,000 per vial |
| Xeomin® | 100 units | ₹10,000–14,000 per vial |
| Dysport® | 500 units | ₹20,000–28,000 per vial |
- Not included in NLEM; not under NPPA price control
- Available in tertiary hospitals through institutional procurement at lower rates
- Private sector pricing variable
CLINICAL PEARLS
- Unit non-interchangeability is critical — Botox/Xeomin units differ from Dysport; approximately 2.5–3 Dysport units ≈ 1 Botox unit (not exact; follow product-specific dosing)
- Reconstitution — Use preservative-free 0.9% saline only; use within 4 hours of reconstitution (24 hours if refrigerated for some products)
- Injection technique — EMG or ultrasound guidance significantly improves outcomes in deep muscles; mandatory for strabismus and recommended for spasticity
- Resistance management — If efficacy wanes, consider neutralising antibodies; minimise total dose per session and maximise inter-injection intervals; switching brands may help in some cases
- Patient counselling — Effect onset in 3–7 days; peak at 2–4 weeks; duration 3–4 months; set realistic expectations
- Post-injection care — Avoid rubbing injection site; remain upright for 4 hours post-facial injection to prevent toxin spread
TAGS
botulinum toxin A; botox; dystonia; spasticity; chronic migraine; hyperhidrosis; overactive bladder; neurotoxin; specialist-only; injection therapy
VERSION
RxIndia v0.2 — 03 Feb 2026
REFERENCES
- CDSCO approved product inserts (Allergan BOTOX®, Xeomin®, Dysport® India)
- Indian Pharmacopoeia
- AIIMS Drug Formulary — Neurology & Paediatric Neurology Departments
- Neurology Society of India clinical practice recommendations
- Indian Urological Society guidelines (intravesical use)
- API Textbook of Medicine
- Goodman & Gilman’s: The Pharmacological Basis of Therapeutics
- NFI 2021
- RCT evidence (sialorrhoea, chronic migraine — for off-label indications only)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.